Helsinn publishes PROVe MF-CTCL study providing new data for mechlorethamine gel use in a real-world setting Helsinn publishes PROVe MF-CTCL study providing new data for mechlorethamine gel use in a real-world setting Lugano, Switzerland, March 18, 2021 – Helsinn, a Swiss pharmaceutical group focused on...

Helsinn Therapeutics (U.S.), Inc. waives copay fees for cancer-treating drug VALCHLOR® (mechlorethamine) gel to ensure eligible patients have access to treatment during the COVID-19 crisis Helsinn Therapeutics (U.S.), Inc. waives copay fees for cancer-treating drug VALCHLOR® (mechlorethamine) gel to ensure eligible patients have access to treatment during the COVID-19 crisis Iselin,...

New Insights on Mechlorethamine/Chlormethine gel presented at 4th World Congress of Cutaneous Lymphomas New Insights on Mechlorethamine/Chlormethine gel presented at 4th World Congress of Cutaneous Lymphomas Lugano, Switzerland, February 14, 2020 – Helsinn, the Swiss pharmaceutical group focused on...